* Data from separate Product Monographs; comparative clinical significance is unknown.

MIRENA^® (levonorgestrel-releasing intrauterine system) is indicated for:

• conception control for maximum up to 5 years
• treatment of idiopathic menorrhagia following appropriate diagnostic investigation in women accepting the contraceptive effect of MIRENA^®

Consult the Product Monograph at https://www.bayer.com/sites/default/files/mirena-pm-en.pdf for information about:

• Contraindications in patients with known/suspected pregnancy; current/recurrent PID; lower genital tract infection; postpartum endometritis; undiagnosed abnormal uterine bleeding; uterine anomalies, including fibroids if they distort the uterine cavity; uterine or cervical malignancy; known/suspected progestin-dependent neoplasia, including breast cancer; cervicitis; cervical dysplasia; active liver disease/dysfunction; actual benign or malignant liver tumours; septic abortion within the previous 3 months; bacterial endocarditis; established immunodeficiency; acute malignancies affecting blood or leukemias; recent trophoblastic disease while hCG levels are elevated
• Most serious warnings and precautions regarding sexually transmitted infections, cigarette smoking, uterine perforation
• Other relevant warnings and precautions regarding Health Canada not authorizing an indication for pediatric or geriatric use (due to no data being available to Health Canada) or for use in post-menopausal women; hormonal contraceptive use in breastfeeding women; use in only women of child-bearing age; postcoital contraception; breast cancer/breast self-examination; current/history of cardiovascular disease; significant elevation of blood pressure in previously normotensive or hypertensive subjects; congenital/valvular heart disease; migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia, severe headache, marked increase in blood pressure, or active or previous severe arterial disease such as stroke or myocardial infarction; patients with diabetes/those with a family history of diabetes; gastrointestinal disorders; bleeding irregularities after prolonged use; arterial and venous thromboembolism; increased risk of VTE with prolonged immobilization, major surgery, or trauma and in those with varicose veins and leg casts; impaired liver function; jaundice/history of pregnancy-related cholestasis; eye problems/discomfort, including those relating to contact lens use; history of emotional disturbances, especially the depressive type; ectopic pregnancy; complete or partial expulsion of MIRENA^®; ovarian cysts/enlarged ovarian follicles; increased risk of PID for 20 days following insertion; no alterations to the course of future fertility; sepsis; skin and subcutaneous tissue disorders; discussion of efficacy, risks and side effects before insertion; perform thorough history and physical examination prior to insertion, 4–12 weeks after insertion, and ≥1/year thereafter
• Conditions of clinical use, adverse reactions, drug interactions and dosing

The Product Monograph is also available by calling 1-800-265-7382.

Start a conversation about KYLEENA^® and have your patients visit kyleena.ca for helpful resources

(for full access, enter the Drug Identification Number [DIN] 02459523 when requested).